Reason for Delay in Posting Financial Report: State below in reasonable detail why the Annual/Quarterly Report could not be filed within the prescribed time period.
THE ACCOUNTANT HAD CONTRACTED COVID
Anticipated Filing Date:
[Please note that the filing of this notification grants issuers 5 additional calendar days to post a Quarterly or Interim Report and 15 calendar days to post an Annual Report.]
INTERIM REPORT 5 DAYS
Person to contact regarding this notification:
Officer/Director Signature:
Date: Feb 14, 2022
Date: Feb 14, 2022
Signature: /s/
Signature: /s/
Name: Tito Di Marco
Name: Tito Di Marco
Title: CEO/Director
Title: CEO/Director
Instructions to post Notification of Late Filing in www.OTCIQ.com:
Fill out this Notification of Late Filing form and convert the file to a PDF
Log in to www.OTCIQ.com and click "Add Financial Report" on the left hand navigation
Select Dissemination Date "Immediate"
Under Report Type, select "Notification of Late Filing"
Enter Period End Date corresponding to the quarter/fiscal year end date for which this Notice is being filed
Click "Browse" and select the PDF saved in step 1 above.
A preview of the document will appear next. Please make sure to review the entire document & scroll down to click the "Submit" button. Your Notification of Late Filing will appear within a few minutes on otcmarkets.com
Alternative Reporting companies on the Pink Current tier may utilize the Notification of Late Filing to receive the extension. The Notification must be submitted by the applicable reporting deadline to qualify for the extension.
OTCQB and OTCQX non-SEC reporting companies may also post this document to remain compliant with OTC reporting requirements.
Conditional Filing Relief for Companies Affected by the Coronavirus:Issuer must specifically disclose a summary of why relief is needed in the Notification of Late Filing in order to receive the 45 day extension.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Galileo Life Sciences Inc. published this content on 14 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 February 2022 19:52:04 UTC.
Modern Mobility Aids Inc., formerly Galileo Life Sciences, Inc., is focused on the life sciences and healthcare industry. The Company is focused on acquiring companies within the biopharmaceutical sector, to focus research and development, and to create a manufacturing capacity in the three segments, which include contract research and manufacturing for life sciences companies, drug and device delivery format packaging and strategic development and production alliances. The Company plans to acquire or invest in multiple licensed producers in Canada and the United States. The Company is focused on exploiting the opportunities presented in the medical marijuana arena. The Company's subsidiary is MDRM Group (Canada) Ltd. The Company also focuses on investing in licensed producers in Canada and the United States, as well as suppliers to the industry. The Company has not generated any revenues and had not commenced any revenue generating activities.